Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
MSD Korea, the local affiliate of U.S.-based pharmaceutical company Merck & Co. on Tuesday said it has named former strategy head of MSD Japan Avi Ben-Shoshan as its new managing director.
Ben-Shoshan will replace former chief of MSD Korea Hyun Dong-wook, who has led the company for eight years since 2008. Hyun has been named as the global brand leader of Merck & Co.’s global Human Papillomavirus Vaccine business.
“I’m looking forward to joining MSD Korea and to continuing the success that Don (Dong-wook) and his team have had in serving customers and patients in Korea,” Ben-Shoshan said in a statement.
Ben-Shoshan began his career in the pharmaceutical industry by joining the Canadian branch of U.S.-based Pfizer in 1995, where he built experience in market research, new product planning, market access and business development.
After joining MSD Israel in 2003, he became the branch’s managing director in 2011. He later served as MSD Japan’s head of strategy from 2014, and will now head MSD Korea.
By Sohn Ji-young (jys@heraldcorp.com)
